메뉴 건너뛰기




Volumn 35, Issue 9, 2017, Pages 994-1001

Genomics, signaling, and treatment of waldenström macroglobulinemia

Author keywords

[No Author keywords available]

Indexed keywords

ARID1A PROTEIN; BRUTON TYROSINE KINASE; CD79A ANTIGEN; CD79B ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HEMATOPOIETIC CELL KINASE; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE LYN; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

EID: 85016288459     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.0814     Document Type: Review
Times cited : (78)

References (72)
  • 1
    • 0037396214 scopus 로고    scopus 로고
    • Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    • Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30: 110-115, 2003
    • (2003) Semin Oncol , vol.30 , pp. 110-115
    • Owen, R.G.1    Treon, S.P.2    Al-Katib, A.3
  • 3
    • 0032520265 scopus 로고    scopus 로고
    • Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994
    • Groves FD, Travis LB, Devesa SS, et al: Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994. Cancer 82: 1078-1081, 1998
    • (1998) Cancer , vol.82 , pp. 1078-1081
    • Groves, F.D.1    Travis, L.B.2    Devesa, S.S.3
  • 4
    • 79953699058 scopus 로고    scopus 로고
    • Associated malignancies in patients with Waldenström's macroglobulinemia and their kin
    • Hanzis C, Ojha RP, Hunter Z, et al: Associated malignancies in patients with Waldenström's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk 11: 88-92, 2011
    • (2011) Clin Lymphoma Myeloma Leuk , vol.11 , pp. 88-92
    • Hanzis, C.1    Ojha, R.P.2    Hunter, Z.3
  • 5
    • 84856362228 scopus 로고    scopus 로고
    • Risk of second cancers in Waldenström macroglobulinemia
    • Varettoni M, Tedeschi A, Arcaini L, et al: Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol 23: 411-415, 2012
    • (2012) Ann Oncol , vol.23 , pp. 411-415
    • Varettoni, M.1    Tedeschi, A.2    Arcaini, L.3
  • 6
    • 33644681507 scopus 로고    scopus 로고
    • Characterization of familial Waldenstrom's macroglobulinemia
    • Treon SP, Hunter ZR, Aggarwal A, et al: Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 17: 488-494, 2006
    • (2006) Ann Oncol , vol.17 , pp. 488-494
    • Treon, S.P.1    Hunter, Z.R.2    Aggarwal, A.3
  • 7
    • 54049129700 scopus 로고    scopus 로고
    • Risk of lymphoproliferative disorders among firstdegree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A populationbased study in Sweden
    • Kristinsson SY, Björkholm M, Goldin LR, et al: Risk of lymphoproliferative disorders among firstdegree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A populationbased study in Sweden. Blood 112: 3052-3056, 2008
    • (2008) Blood , vol.112 , pp. 3052-3056
    • Kristinsson, S.Y.1    Björkholm, M.2    Goldin, L.R.3
  • 8
    • 34548830816 scopus 로고    scopus 로고
    • Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families
    • McMaster ML, Csako G, Giambarresi TR, et al: Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 13: 5063-5069, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 5063-5069
    • McMaster, M.L.1    Csako, G.2    Giambarresi, T.R.3
  • 9
    • 0032854758 scopus 로고    scopus 로고
    • Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2
    • Ogmundsdóttir HM, Sveinsdóttir S, Sigfússon A, et al: Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. Clin Exp Immunol 117: 252-260, 1999
    • (1999) Clin Exp Immunol , vol.117 , pp. 252-260
    • Ogmundsdóttir, H.M.1    Sveinsdóttir, S.2    Sigfússon, A.3
  • 10
    • 84974621496 scopus 로고    scopus 로고
    • Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
    • Roccaro AM, Sacco A, Shi J, et al: Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood 127: 2598-2606, 2016
    • (2016) Blood , vol.127 , pp. 2598-2606
    • Roccaro, A.M.1    Sacco, A.2    Shi, J.3
  • 11
    • 84869472021 scopus 로고    scopus 로고
    • Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia
    • Treon SP, Tripsas C, Hanzis C, et al: Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 12: 433-437, 2012
    • (2012) Clin Lymphoma Myeloma Leuk , vol.12 , pp. 433-437
    • Treon, S.P.1    Tripsas, C.2    Hanzis, C.3
  • 12
    • 84926193835 scopus 로고    scopus 로고
    • Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival
    • Steingrímsson V, Lund SH, Turesson I, et al: Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival. Blood 125: 2174-2175, 2015
    • (2015) Blood , vol.125 , pp. 2174-2175
    • Steingrímsson, V.1    Lund, S.H.2    Turesson, I.3
  • 13
    • 0037108295 scopus 로고    scopus 로고
    • Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions
    • Schop RF, Kuehl WM, Van Wier SA, et al: Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100: 2996-3001, 2002
    • (2002) Blood , vol.100 , pp. 2996-3001
    • Schop, R.F.1    Kuehl, W.M.2    Van Wier, S.A.3
  • 14
    • 33845501643 scopus 로고    scopus 로고
    • 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
    • Ocio EM, Schop RF, Gonzalez B, et al: 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 136: 80-86, 2007
    • (2007) Br J Haematol , vol.136 , pp. 80-86
    • Ocio, E.M.1    Schop, R.F.2    Gonzalez, B.3
  • 15
    • 67649566146 scopus 로고    scopus 로고
    • Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: A multicenter study
    • Chang H, Qi C, Trieu Y, et al: Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: A multicenter study. Clin Lymphoma Myeloma 9: 36-38, 2009
    • (2009) Clin Lymphoma Myeloma , vol.9 , pp. 36-38
    • Chang, H.1    Qi, C.2    Trieu, Y.3
  • 16
    • 84875653870 scopus 로고    scopus 로고
    • Chromosomal aberrations and their prognostic value in a series of 174 untreated patients withWaldenström's macroglobulinemia
    • Nguyen-Khac F, Lambert J, Chapiro E, et al: Chromosomal aberrations and their prognostic value in a series of 174 untreated patients withWaldenström's macroglobulinemia. Haematologica 98: 649-654, 2013
    • (2013) Haematologica , vol.98 , pp. 649-654
    • Nguyen-Khac, F.1    Lambert, J.2    Chapiro, E.3
  • 17
    • 0036203951 scopus 로고    scopus 로고
    • Trisomy 4 as the sole cytogenetic abnormality in a Waldenström macroglobulinemia
    • Rivera AI, Li MM, Beltran G, et al: Trisomy 4 as the sole cytogenetic abnormality in a Waldenström macroglobulinemia. Cancer Genet Cytogenet 133: 172-173, 2002
    • (2002) Cancer Genet Cytogenet , vol.133 , pp. 172-173
    • Rivera, A.I.1    Li, M.M.2    Beltran, G.3
  • 18
    • 0037397404 scopus 로고    scopus 로고
    • 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia
    • Avet-Loiseau H, Garand R, LodéL, et al: 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 30: 153-155, 2003
    • (2003) Semin Oncol , vol.30 , pp. 153-155
    • Avet-Loiseau, H.1    Garand, R.2    Lodé, L.3
  • 19
    • 84865475885 scopus 로고    scopus 로고
    • MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
    • Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367: 826-833, 2012
    • (2012) N Engl J Med , vol.367 , pp. 826-833
    • Treon, S.P.1    Xu, L.2    Yang, G.3
  • 20
    • 84877343691 scopus 로고    scopus 로고
    • MYD88 L265P inWaldenströmmacroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
    • Xu L, Hunter ZR, Yang G, et al: MYD88 L265P inWaldenströmmacroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121: 2051-2058, 2013
    • (2013) Blood , vol.121 , pp. 2051-2058
    • Xu, L.1    Hunter, Z.R.2    Yang, G.3
  • 21
    • 84878423649 scopus 로고    scopus 로고
    • Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
    • Varettoni M, Arcaini L, Zibellini S, et al: Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 121: 2522-2528, 2013
    • (2013) Blood , vol.121 , pp. 2522-2528
    • Varettoni, M.1    Arcaini, L.2    Zibellini, S.3
  • 22
    • 84881482021 scopus 로고    scopus 로고
    • MYD88 L265P is amarker highly characteristic of, but not restricted to,Waldenström's macroglobulinemia
    • Jiménez C, Sebastián E, Chillón MC, et al: MYD88 L265P is amarker highly characteristic of, but not restricted to,Waldenström's macroglobulinemia. Leukemia 27: 1722-1728, 2013
    • (2013) Leukemia , vol.27 , pp. 1722-1728
    • Jiménez, C.1    Sebastián, E.2    Chillón, M.C.3
  • 23
    • 84879404052 scopus 로고    scopus 로고
    • MYD88 L265P mutation in Waldenstrom macroglobulinemia
    • Poulain S, Roumier C, Decambron A, et al: MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121: 4504-4511, 2013
    • (2013) Blood , vol.121 , pp. 4504-4511
    • Poulain, S.1    Roumier, C.2    Decambron, A.3
  • 24
    • 84895459238 scopus 로고    scopus 로고
    • Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
    • Ansell SM, Hodge LS, Secreto FJ, et al: Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J 4: E183, 2014
    • (2014) Blood Cancer J , vol.4 , pp. e183
    • Ansell, S.M.1    Hodge, L.S.2    Secreto, F.J.3
  • 25
    • 84938862553 scopus 로고    scopus 로고
    • MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia
    • Treon SP, Xu L, Hunter Z: MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med 373: 584-586, 2015
    • (2015) N Engl J Med , vol.373 , pp. 584-586
    • Treon, S.P.1    Xu, L.2    Hunter, Z.3
  • 26
    • 84915804247 scopus 로고    scopus 로고
    • MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
    • Poulain S, Boyle EM, Roumier C, et al: MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol 167: 506-513, 2014
    • (2014) Br J Haematol , vol.167 , pp. 506-513
    • Poulain, S.1    Boyle, E.M.2    Roumier, C.3
  • 27
    • 84995444989 scopus 로고    scopus 로고
    • MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinemia
    • 10.1111/bjh.14386 [epub ahead of print on October 17
    • Gustine J, Meid K, Hunter ZR, et al: MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinemia. Br J Haematol 10.1111/bjh.14386 [epub ahead of print on October 17, 2016]
    • (2016) Br J Haematol
    • Gustine, J.1    Meid, K.2    Hunter, Z.R.3
  • 28
    • 84897511040 scopus 로고    scopus 로고
    • The genomic landscape of Waldenstom macroglobulinemia is characterized by highly recurring MYD88 and WHIMlike CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
    • Hunter ZR, Xu L, Yang G, et al: The genomic landscape of Waldenstom macroglobulinemia is characterized by highly recurring MYD88 and WHIMlike CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123: 1637-1646, 2014
    • (2014) Blood , vol.123 , pp. 1637-1646
    • Hunter, Z.R.1    Xu, L.2    Yang, G.3
  • 29
    • 85016322876 scopus 로고    scopus 로고
    • Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom's macroglobulinemia, and associated with CXCR4 mutations status
    • Amsterdam, The Netherlands, October (abstr W7
    • Tsakmaklis N: Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom's macroglobulinemia, and associated with CXCR4 mutations status. IXth International Workshop on Waldenstrom's Macroglobulinemia, Amsterdam, The Netherlands, October 5-8, 2016 (abstr W7)
    • (2016) IXth International Workshop on Waldenstrom's Macroglobulinemia , pp. 5-8
    • Tsakmaklis, N.1
  • 30
    • 85016235316 scopus 로고    scopus 로고
    • Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom's Macroglobulinemia
    • Treon SP, Tsakmaklis N, Meid K, et al: Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom's Macroglobulinemia. Blood 128: 2984, 2016
    • (2016) Blood , vol.128 , pp. 2984
    • Treon, S.P.1    Tsakmaklis, N.2    Meid, K.3
  • 31
    • 84887396799 scopus 로고    scopus 로고
    • MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
    • VarettoniM, Zibellini S, Arcaini L, et al: MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 122: 2284-2285, 2013
    • (2013) Blood , vol.122 , pp. 2284-2285
    • VarettoniM Zibellini, S.1    Arcaini, L.2
  • 32
    • 84900443158 scopus 로고    scopus 로고
    • Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
    • Treon SP, Cao Y, Xu L, et al: Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123: 2791-2796, 2014
    • (2014) Blood , vol.123 , pp. 2791-2796
    • Treon, S.P.1    Cao, Y.2    Xu, L.3
  • 33
    • 77953714711 scopus 로고    scopus 로고
    • Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
    • Lin SC, Lo YC, Wu H: Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890, 2010
    • (2010) Nature , vol.465 , pp. 885-890
    • Lin, S.C.1    Lo, Y.C.2    Wu, H.3
  • 34
    • 79551686422 scopus 로고    scopus 로고
    • Oncogenically active MYD88 mutations in human lymphoma
    • Ngo VN, Young RM, Schmitz R, et al: Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119, 2011
    • (2011) Nature , vol.470 , pp. 115-119
    • Ngo, V.N.1    Young, R.M.2    Schmitz, R.3
  • 35
    • 84883876958 scopus 로고    scopus 로고
    • A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
    • Yang G, Zhou Y, Liu X, et al: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122: 1222-1232, 2013
    • (2013) Blood , vol.122 , pp. 1222-1232
    • Yang, G.1    Zhou, Y.2    Liu, X.3
  • 36
    • 84963692137 scopus 로고    scopus 로고
    • Targeting myddosome assembly in Waldenstrom macroglobulinaemia
    • 10.1111/bjh.14103 [epub ahead of print on April 13
    • Liu X, Hunter ZR, Xu L, et al: Targeting myddosome assembly in Waldenstrom macroglobulinaemia. Br J Haematol 10.1111/bjh.14103 [epub ahead of print on April 13, 2016]
    • (2016) Br J Haematol
    • Liu, X.1    Hunter, Z.R.2    Xu, L.3
  • 37
    • 84994683978 scopus 로고    scopus 로고
    • HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
    • Yang G, Buhrlage SJ, Tan L, et al: HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood 127: 3237-3252, 2016
    • (2016) Blood , vol.127 , pp. 3237-3252
    • Yang, G.1    Buhrlage, S.J.2    Tan, L.3
  • 38
    • 84962327986 scopus 로고    scopus 로고
    • Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia
    • Poulain S, Roumier C, Venet-Caillault A, et al: Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia. Clin Cancer Res 22: 1480-1488, 2016
    • (2016) Clin Cancer Res , vol.22 , pp. 1480-1488
    • Poulain, S.1    Roumier, C.2    Venet-Caillault, A.3
  • 39
    • 84958947359 scopus 로고    scopus 로고
    • Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia
    • Xu L, Hunter ZR, Tsakmaklis N, et al: Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia. Br J Haematol 172: 735-744, 2016
    • (2016) Br J Haematol , vol.172 , pp. 735-744
    • Xu, L.1    Hunter, Z.R.2    Tsakmaklis, N.3
  • 40
    • 84930259756 scopus 로고    scopus 로고
    • MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
    • Schmidt J, Federmann B, Schindler N, et al: MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol 169: 795-803, 2015
    • (2015) Br J Haematol , vol.169 , pp. 795-803
    • Schmidt, J.1    Federmann, B.2    Schindler, N.3
  • 41
    • 0037656291 scopus 로고    scopus 로고
    • Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease
    • Hernandez PA, Gorlin RJ, Lukens JN, et al: Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34: 70-74, 2003
    • (2003) Nat Genet , vol.34 , pp. 70-74
    • Hernandez, P.A.1    Gorlin, R.J.2    Lukens, J.N.3
  • 42
    • 84863670283 scopus 로고    scopus 로고
    • WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4
    • LiuQ, Chen H, Ojode T, et al: WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 120: 181-189, 2012
    • (2012) Blood , vol.120 , pp. 181-189
    • LiuQ Chen, H.1    Ojode, T.2
  • 43
    • 0030712369 scopus 로고    scopus 로고
    • Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization
    • Haribabu B, Richardson RM, Fisher I, et al: Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 272: 28726-28731, 1997
    • (1997) J Biol Chem , vol.272 , pp. 28726-28731
    • Haribabu, B.1    Richardson, R.M.2    Fisher, I.3
  • 44
    • 84920679727 scopus 로고    scopus 로고
    • The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia
    • Cao Y, Hunter ZR, Liu X, et al: The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia 29: 169-176, 2015
    • (2015) Leukemia , vol.29 , pp. 169-176
    • Cao, Y.1    Hunter, Z.R.2    Liu, X.3
  • 45
    • 84922832325 scopus 로고    scopus 로고
    • CXCR4 WHIMlike frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 (L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
    • Cao Y, Hunter ZR, Liu X, et al: CXCR4 WHIMlike frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 (L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol 168: 701-707, 2015
    • (2015) Br J Haematol , vol.168 , pp. 701-707
    • Cao, Y.1    Hunter, Z.R.2    Liu, X.3
  • 46
    • 84903647822 scopus 로고    scopus 로고
    • C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
    • Roccaro AM, Sacco A, Jimenez C, et al: C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 123: 4120-4131, 2014
    • (2014) Blood , vol.123 , pp. 4120-4131
    • Roccaro, A.M.1    Sacco, A.2    Jimenez, C.3
  • 47
    • 77957946398 scopus 로고    scopus 로고
    • ARID1A mutations in endometriosis-associated ovarian carcinomas
    • Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010
    • (2010) N Engl J Med , vol.363 , pp. 1532-1543
    • Wiegand, K.C.1    Shah, S.P.2    Al-Agha, O.M.3
  • 48
    • 80155131218 scopus 로고    scopus 로고
    • ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers
    • Guan B, Wang T-L, Shih IeM: ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718-6727, 2011
    • (2011) Cancer Res , vol.71 , pp. 6718-6727
    • Guan, B.1    Wang, T.-L.2    Shih IeM.3
  • 49
    • 84923407069 scopus 로고    scopus 로고
    • B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
    • Seda V, Mraz M: B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 94: 193-205, 2015
    • (2015) Eur J Haematol , vol.94 , pp. 193-205
    • Seda, V.1    Mraz, M.2
  • 50
    • 84938994998 scopus 로고    scopus 로고
    • Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
    • Wilson WH, Young RM, Schmitz R, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21: 922-926, 2015
    • (2015) Nat Med , vol.21 , pp. 922-926
    • Wilson, W.H.1    Young, R.M.2    Schmitz, R.3
  • 51
    • 84959473340 scopus 로고    scopus 로고
    • Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling
    • Argyropoulos KV, Vogel R, Ziegler C, et al: Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia 30: 1116-1125, 2016
    • (2016) Leukemia , vol.30 , pp. 1116-1125
    • Argyropoulos, K.V.1    Vogel, R.2    Ziegler, C.3
  • 52
    • 0032492994 scopus 로고    scopus 로고
    • Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes
    • Chan VWF, Lowell CA, DeFranco AL: Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes. Curr Biol 8: 545-553, 1998
    • (1998) Curr Biol , vol.8 , pp. 545-553
    • Chan, V.W.F.1    Lowell, C.A.2    DeFranco, A.L.3
  • 53
    • 85016265468 scopus 로고    scopus 로고
    • Genetic characterization of Waldenstrom macroglobulinemia by next generation sequencing: An analysis of fourteen genes in a series of 61 patients
    • (abstr 2971)
    • Jimenez C, Prieto-Conde I, García-Álvarez M, et al: Genetic characterization of Waldenstrom macroglobulinemia by next generation sequencing: An analysis of fourteen genes in a series of 61 patients. Blood 126, 2015 (abstr 2971)
    • (2015) Blood , vol.126
    • Jimenez, C.1    Prieto-Conde, I.2    García-Álvarez, M.3
  • 54
    • 85031724148 scopus 로고    scopus 로고
    • Whole-exome sequencing of Waldenstrom Macroglobulinemia transformation into aggressive lymphoma
    • (abstr 4101)
    • Alonso S, Jimenez C, Alcoceba M, et al: Whole-exome sequencing of Waldenstrom Macroglobulinemia transformation into aggressive lymphoma. Blood 128, 2016 (abstr 4101)
    • (2016) Blood , vol.128
    • Alonso, S.1    Jimenez, C.2    Alcoceba, M.3
  • 55
    • 80052029516 scopus 로고    scopus 로고
    • Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
    • Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303, 2011
    • (2011) Nature , vol.476 , pp. 298-303
    • Morin, R.D.1    Mendez-Lago, M.2    Mungall, A.J.3
  • 56
    • 84857942952 scopus 로고    scopus 로고
    • Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by wholeexome sequencing
    • Lohr JG, Stojanov P, Lawrence MS, et al: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by wholeexome sequencing. Proc Natl Acad Sci USA 109: 3879-3884, 2012
    • (2012) Proc Natl Acad Sci USA , vol.109 , pp. 3879-3884
    • Lohr, J.G.1    Stojanov, P.2    Lawrence, M.S.3
  • 57
    • 84905995241 scopus 로고    scopus 로고
    • Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia
    • Zhou Y, Liu X, Xu L, et al: Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. Br J Haematol 166: 677-689, 2014
    • (2014) Br J Haematol , vol.166 , pp. 677-689
    • Zhou, Y.1    Liu, X.2    Xu, L.3
  • 58
    • 33847185954 scopus 로고    scopus 로고
    • Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
    • Gutiérrez NC, Ocio EM, de Las Rivas J, et al: Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21: 541-549, 2007
    • (2007) Leukemia , vol.21 , pp. 541-549
    • Gutiérrez, N.C.1    Ocio, E.M.2    De Las Rivas, J.3
  • 59
    • 33750619898 scopus 로고    scopus 로고
    • Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    • Chng WJ, Schop RF, Price-Troska T, et al: Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 108: 2755-2763, 2006
    • (2006) Blood , vol.108 , pp. 2755-2763
    • Chng, W.J.1    Schop, R.F.2    Price-Troska, T.3
  • 60
    • 84981495262 scopus 로고    scopus 로고
    • Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia
    • Hunter ZR, Xu L, Yang G, et al: Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood 128: 827-838, 2016
    • (2016) Blood , vol.128 , pp. 827-838
    • Hunter, Z.R.1    Xu, L.2    Yang, G.3
  • 61
    • 84981510933 scopus 로고    scopus 로고
    • Biologically meaningful changes in cytokine and chemokine production following Ibrutinib therapy in Waldenstrom's Macroglobulinemia
    • (abstr P312)
    • Vos JM, Tsakmaklis N, Brodsky PS, et al: Biologically meaningful changes in cytokine and chemokine production following Ibrutinib therapy in Waldenstrom's Macroglobulinemia. Haematologica 101: 101, 2016 (abstr P312)
    • (2016) Haematologica , vol.101 , pp. 101
    • Vos, J.M.1    Tsakmaklis, N.2    Brodsky, P.S.3
  • 63
    • 84987788570 scopus 로고    scopus 로고
    • Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
    • Leblond V, Kastritis E, Advani R, et al: Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood 128: 1321-1328, 2016
    • (2016) Blood , vol.128 , pp. 1321-1328
    • Leblond, V.1    Kastritis, E.2    Advani, R.3
  • 64
    • 84927155030 scopus 로고    scopus 로고
    • Ibrutinib in previously treated Waldenström's macroglobulinemia
    • Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 372: 1430-1440, 2015
    • (2015) N Engl J Med , vol.372 , pp. 1430-1440
    • Treon, S.P.1    Tripsas, C.K.2    Meid, K.3
  • 65
    • 85016288716 scopus 로고    scopus 로고
    • Single agent ibrutinib in rituximab-refractory patients with Waldenström's macroglobulinemia: Results from a multicenter, open-label phase 3 substudy (iNNOVATETM)
    • in press)
    • Dimopoulos MA, Trotman J, Tedeschi A, et al: Single agent ibrutinib in rituximab-refractory patients with Waldenström's macroglobulinemia: Results from a multicenter, open-label phase 3 substudy (iNNOVATETM). Lancet Oncol (in press)
    • Lancet Oncol
    • Dimopoulos, M.A.1    Trotman, J.2    Tedeschi, A.3
  • 66
    • 85016243664 scopus 로고    scopus 로고
    • Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia
    • 10.1158/1078-0432.CCR-16-1918 [ epub ahead of print on November 11
    • Treon SP, Meid K, Tripsas C, et al: Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia. Clin Cancer Res 10.1158/1078-0432.CCR-16-1918 [epub ahead of print on November 11, 2016]
    • (2016) Clin Cancer Res
    • Treon, S.P.1    Meid, K.2    Tripsas, C.3
  • 67
    • 84904916820 scopus 로고    scopus 로고
    • Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
    • Treon SP, Tripsas CK, Meid K, et al: Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 124: 503-510, 2014
    • (2014) Blood , vol.124 , pp. 503-510
    • Treon, S.P.1    Tripsas, C.K.2    Meid, K.3
  • 68
    • 85038420830 scopus 로고    scopus 로고
    • Ixazomib, dexamethasone, and rituximab (IDR) as primary therapy for symptomatic symptomatic Waldenstrom macroglobulinemia
    • (abstr 2956)
    • Castillo JJ: Ixazomib, dexamethasone, and rituximab (IDR) as primary therapy for symptomatic symptomatic Waldenstrom macroglobulinemia. Blood 128, 2016 (abstr 2956)
    • (2016) Blood , vol.128
    • Castillo, J.J.1
  • 69
    • 84925502851 scopus 로고    scopus 로고
    • Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
    • Bitler BG, Aird KM, Garipov A, et al: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21: 231-238, 2015
    • (2015) Nat Med , vol.21 , pp. 231-238
    • Bitler, B.G.1    Aird, K.M.2    Garipov, A.3
  • 70
    • 84940050343 scopus 로고    scopus 로고
    • How I treat Waldenström macroglobulinemia
    • Treon SP: How I treat Waldenström macroglobulinemia. Blood 126: 721-732, 2015
    • (2015) Blood , vol.126 , pp. 721-732
    • Treon, S.P.1
  • 71
    • 84931563809 scopus 로고    scopus 로고
    • The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells
    • Cao Y, Yang G, Hunter ZR, et al: The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 170: 134-138, 2015
    • (2015) Br J Haematol , vol.170 , pp. 134-138
    • Cao, Y.1    Yang, G.2    Hunter, Z.R.3
  • 72
    • 84997558826 scopus 로고    scopus 로고
    • A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma
    • (abstr)
    • Gerecitano JF, Roberts AW, Seymour JF et al: A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood 126: 254, 2015 (abstr)
    • (2015) Blood , vol.126 , pp. 254
    • Gerecitano, J.F.1    Roberts, A.W.2    Seymour, J.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.